What Тридуктан Treats: Main Uses and Benefits

Trimetazidine is commonly used as add-on therapy for the symptomatic treatment of stable angina pectoris, a chronic condition where the heart experiences recurring discomfort in this condition marked by increased physiological stress. It is indicated for adult patients who are inadequately controlled by or intolerant to first-line antianginal therapies. The medicine is applied in addressing symptoms related to physical discomfort, specifically episodic chest pressure, discomfort, or pain, and functional limitations, such as symptoms that interfere with daily functioning.

This medication may assist with a reduction in the frequency of angina attacks and supports patients during episodes of heightened discomfort. This therapy is commonly used to help with improving physical capacity and contributes to easing the overall symptom load. The drug assists with maintaining functional stability when the heart experiences symptoms linked to organ-specific functional stress during physical exertion.

---

Quick Fact: Focus on Recurrent Symptom Patterns

Eligibility Profile: Who Can and Cannot Use Trimetazidine

Тридуктан (Trimetazidine) is subject to strict eligibility rules based on official government regulatory documents. These rules define absolute exclusions (contraindications) and populations where use is restricted or not recommended.

Contraindicated Populations (Must NOT Use)

Condition / Population	Eligibility Status	Basis
Movement Disorders	Contraindicated	Presence of Parkinson's disease, Parkinsonian symptoms, tremors, or Restless Legs Syndrome.
Severe Renal Impairment	Contraindicated	Creatinine clearance below 30 ml/min.
Hypersensitivity	Contraindicated	Allergy to trimetazidine or any excipient.

---

Populations Requiring Restriction or Special Consideration

• Children and Adolescents (under 18 years): Use is not recommended due to insufficient data on safety and effectiveness.
• Moderate Renal Impairment: Use is restricted and requires a dose adjustment (creatinine clearance 30 –60 ml/min).
• Elderly Patients (over 75 years): Caution is required, particularly due to the potential for reduced kidney function.
• Pregnancy and Breastfeeding: Use is not recommended; it is preferable to avoid taking the medicine during pregnancy and while breastfeeding.

Interactions with other medicines and products

Official regulatory documentation establishes that Trimetazidine is associated with a distinct interaction profile, primarily characterized by a lack of conventional drug–drug interactions. Regulatory studies have found no evidence of clinically significant interactions with other medicinal products, including common cardiovascular agents. Furthermore, Trimetazidine is documented as neither an inducer nor an inhibitor of common metabolic enzymes (drug hydroxylation), and its pharmacokinetic characteristics are not influenced by meals or foodstuffs. This documented lack of interaction results in no requirement for timing separation from co-administered agents.

Interaction Constraint	Official Restriction/Caution
Contraindicated Conditions	Use is strictly prohibited in patients with severe renal impairment (creatinine clearance less than 30 ml/min) due to the risk of accumulation, and in those with pre-existing Parkinson’s disease or related movement disorders [due to risk of worsening].
Exposure Considerations	Increased plasma exposure is officially expected in two specific populations: elderly patients (aged 75 and older) and individuals with moderate renal impairment (creatinine clearance 30 –60 ml/min).

The interaction profile is primarily structured by restrictions tied to the patient’s physiological state and health history, rather than interactions with co-administered medicines. The documented constraints emphasize the necessity of adequate renal clearance for the drug's proper elimination and caution regarding specific neurological conditions.

How Тридуктан Works

Тридуктан acts primarily as a partial inhibitor of the enzyme 3-ketoacyl CoA thiolase (3-KAT), a key enzyme in the long-chain fatty acid beta-oxidation pathway.

This biochemical action across the mitochondrial membrane subsequently results in the inhibition of fatty acid uptake and shifts the predominant energy substrate utilization towards glucose oxidation. This shift is achieved through the secondary stimulation of pyruvate dehydrogenase (PDH).

Switching the metabolic pathway increases the ATP production per unit of oxygen consumed (oxygen efficiency). This effect is crucial under conditions of reduced oxygen availability. The mechanism further involves the modulation of the mitochondrial membrane potential and the regulation of ion homeostasis via control over the mitochondrial permeability transition pores ( mPTP). This complex intracellular cascade stabilizes cellular components against metabolic stress.

How to Use Тридуктан: Administration Guidelines

Тридуктан (Trimetazidine dihydrochloride) is used according to specific instructions concerning the correct route, frequency, and dose adjustment based on patient factors.

---

Administration Scope

Feature	Instruction
Route of administration	Oral administration, utilizing the solid modified-release dosage form.
Dosing schedule	The standard adult regimen is 35 mg per unit dose. The typical total daily dose is 70 mg.
Frequency and timing	The medicine is taken on a twice daily (bid) schedule, usually morning and evening.
Timing in relation to meals	Administration must occur during meals to ensure proper delivery and use.
Preparation requirements	The modified-release tablet must be swallowed whole and is not to be chewed or crushed due to its prolonged-release mechanism.

---

Population-Specific Use Adjustments

Dose modification applies to specific patient groups to ensure appropriate use:

• Older Adults (>75 years): The dosage is reduced to 35 mg once daily due to the potential for age-related decline in kidney function.
• Moderate Renal Impairment (CrCl 30–60 mL/min): The dose is adjusted to 35 mg once daily.
• Paediatric Population (<18 years): Administration is not established, as the safety and efficacy have not been determined for this age group.

---

Resulting Procedural Structure

The standard adult dose follows a fixed oral, twice-daily regimen, with ingestion during meals. This structure is modified based on factors such as advanced age or existing moderate renal impairment, which results in a reduction to a once-daily dose. The specific requirement to swallow the tablet whole is essential to maintain the intended drug release over time.

Research evidence / Overview of studies for Тридуктан

Stable Angina Pectoris (Chest Pain)

Research into Тридуктан has primarily focused on its use for stable angina pectoris, which is persistent chest pain or discomfort that happens when the heart muscle doesn't get enough blood.

Most of the available evidence comes from clinical trials, where the medication was studied alongside a person's usual angina treatment. The main goal was to see if adding Тридуктан was associated with a lower frequency of angina attacks or a lower need for short-acting relief medications like nitroglycerin.

The findings from these trials generally suggest that when added to standard treatment, the medication was associated with certain measured changes. These changes were often reported as a lower number of weekly angina attacks and a lower amount of emergency medication use. However, the size of this association can vary across different studies. The existing research mainly involved adults under the age of 75, so the evidence base for very elderly patients is more limited.

Ear-Related Problems

Research has also explored the use of Тридуктан for certain conditions affecting the inner ear. The conditions studied include dizziness (vertigo), ringing in the ears (tinnitus), and hearing loss, in people where the underlying issue was suspected to be related to the blood vessels.

Initial findings from some smaller trials suggest that the medication was associated with measured changes in the symptoms of vertigo and, to a lesser extent, tinnitus and hearing problems. The studies generally aim to see if the medication was associated with a lower intensity or frequency of vertigo episodes or a lower perceived loudness of tinnitus.

However, the evidence for these ear-related indications is generally considered less robust than for angina. There is substantial uncertainty about which specific types of dizziness or tinnitus were most frequently associated with a response to the treatment, and more large-scale studies are needed to describe any potential associations.

Eye-Related Problems

A smaller body of research has investigated the use of Тридуктан for certain eye conditions linked to problems with the blood supply to the eye's retina, such as visual disturbances. The research generally tries to determine if the medication was associated with changes in visual function or blood flow in the eye's small vessels.

The available research is quite limited and consists primarily of small, observational, or preliminary studies. Therefore, the evidence for changes in eye-related problems is preliminary, and it is highly uncertain what kind of impact the medication might have on measures of vision.

Common questions about Тридуктан (FAQ)

Q: Does Тридуктан help with angina (chest pain)?

According to the official product information, Тридуктан is indicated for the treatment of angina pectoris, which is chest pain caused by reduced blood flow to the heart muscle. It is designated for use in adults as an add-on therapy, meaning it is typically used in conjunction with other established heart medications.

Q: Can I use Тридуктан for vertigo (dizziness)?

Regulatory documents state that Тридуктан is used to help manage symptoms associated with vertigo, which is a sensation of spinning or dizziness. Regulatory documents mention this use as part of the symptomatic treatment, typically in cases where standard primary treatments have not provided adequate benefit.

Q: Is Тридуктан used for tinnitus (ringing in the ears)?

Studies and official information indicate that Тридуктан can be used in the symptomatic treatment of tinnitus. Tinnitus is a medical condition involving the perception of sound, often a ringing or buzzing, in the ears when no external sound is present.

Q: What is the active ingredient in Тридуктан?

The active ingredient in Тридуктан is Trimetazidine. This substance is classified as a metabolic agent, often used to help improve cell function under conditions of reduced blood flow. The official label provides details regarding the drug’s pharmacological properties.

Q: What is the difference between Тридуктан MR and other versions?

Тридуктан MR contains Trimetazidine in a modified-release form. Modified-release (MR) means the medicine is formulated to be released slowly into the body over a longer duration. Due to this design, the prescribed administration schedule is generally less frequent than with immediate-release forms, as detailed in the official product information.

How to Store and Dispose of Тридуктан (Trimetazidine)

The storage and disposal instructions for Тридуктан (Trimetazidine modified-release tablets) are mandated by official regulatory documents to maintain product integrity and ensure environmental safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 30°C.
Container	Keep the medicine in its original container to ensure protection.
Handling	The modified-release tablet must be swallowed whole and not crushed or chewed.
Child Safety	Must be kept out of the sight and reach of children.

---

️ Disposal Instructions

Expired or unused medication must be disposed of in accordance with local requirements for pharmaceutical waste. The product should not be disposed of via household waste or wastewater (e.g., flushed down the toilet) to prevent environmental contamination. Consult your pharmacist or local waste authority for proper collection points.